作者：
Wilhelmine,Meeraus [1]
;
Leonie,de Munter [2]
;
Christen M,Gray [3]
;
Akshat,Dwivedi [2]
;
Chloé,Wyndham-Thomas [2]
;
Mario,Ouwens [4]
;
Wendy,Hartig-Merkel [2]
;
Laura,Drikite [2]
;
Griet,Rebry [2]
;
Antonio,Carmona [5]
;
Anke L,Stuurman [6]
;
Thi Yen,Chi Nguyen [1]
;
Guillermo,Mena [2]
;
Ainara,Mira-Iglesias [1]
;
Giancarlo,Icardi [2]
;
Susana,Otero-Romero [7]
;
Sebastian,Baumgartner [8]
;
Charlotte,Martin [9]
;
Sylvia,Taylor [5]
;
Kaatje,Bollaerts [6]
作者单位：
Medical Evidence, Vaccines & Immune Therapies, AstraZeneca, Cambridge, UK.
[1]
P95 Pharmacovigilance and Epidemiology, Leuven, Belgium.
[2]
Real World Science, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
[3]
Medical and Payor Statistics, BioPharmaceutical Business Unit, AstraZeneca, Mölndal, Sweden.
[4]
Vaccine Research Department, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO) de la Comunitat Valenciana, Salud Pública, Valencia, Spain.
[5]
Biomedical Research Consortium of Epidemiology and Public Health (CIBER-ESP), Instituto de Salud Carlos III, Madrid, Spain.
[6]
Preventive Medicine Department - Germans Trias i Pujol University Hospital, Badalona, Spain.
[7]
Autonomous University of Barcelona, Bellaterra, Spain.
[8]
Germans Trias I Pujol Research Institute (IGTP), Badalona, Spain.
[9]
Interuniversity Research Centre on Influenza and Other Transmissible Infections (CIRI-IT), Genoa, Italy.
[10]
Department of Health Sciences, University of Genoa, Italy.
[11]
Servicio de Medicina Preventiva y Epidemiología, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Campus Hospitalari, Barcelona, Spain.
[12]
Fourth Medical Department with Infectious Diseases and Tropical Medicine, Klinik Favoriten/Kaiser-Franz-Josef Hospital, Vienna, Austria.
[13]
Infectious Diseases Department, Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium.
[14]
DOI
10.1016/j.lanepe.2023.100675
PMID
37547274
发布时间
2023-08-08
换一批
换一批
